<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04747002</url>
  </required_header>
  <id_info>
    <org_study_id>WT1-AM-05</org_study_id>
    <nct_id>NCT04747002</nct_id>
  </id_info>
  <brief_title>Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine &quot;Dainippon Sumitomo Phama(DSP)-7888&quot; for Acute Myeloid Leukemia Patients.</brief_title>
  <official_title>Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine &quot;DSP-7888&quot; for Acute Myeloid Leukemia Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osaka University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Japan Agency for Medical Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Osaka University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an investigator-initiated clinical trial (Phase II) using DSP-7888 for acute&#xD;
      myeloid leukemia patients with 1st hematological complete remission (CR). DSP-7888 is a novel&#xD;
      cocktail peptide vaccine designed to induce cytotoxic T lymphocytes that recognize Wilms&#xD;
      Tumor Gene 1 (WT1) peptides.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an investigator-initiated clinical trial (Phase II) using DSP-7888 for acute&#xD;
      myeloid leukemia patients with 1st hematological CR. DSP-7888 is a novel cocktail peptide&#xD;
      vaccine designed to induce cytotoxic T lymphocytes that recognize WT1 peptides. Primary&#xD;
      endpoint is relapse-free survival, and 2nd endpoint is hematological relapse-free survival,&#xD;
      overall survival and adverse event.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2020</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hematological relapse-free survival</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Myeloid Leukemia in Remission</condition>
  <arm_group>
    <arm_group_label>Administration Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who are injected with DSP-7888.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-administration Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients who are only under observation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSP-7888</intervention_name>
    <description>Cocktail peptide vaccine designed to induce cytotoxic T lymphocytes that recognize WT1 peptides</description>
    <arm_group_label>Administration Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. acute myeloid leukemia defined by World Health Organization (WHO) 2016 classification&#xD;
&#xD;
          2. favorable or intermediate risk based on European Leukemia Net (ELN) 2017 risk&#xD;
             classification&#xD;
&#xD;
          3. 1st hematological after chemotherapy&#xD;
&#xD;
          4. Human Leukocyte Antigen (HLA)-A*02:01, 02:06, 24:02&#xD;
&#xD;
          5. 20-80 years old&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance Status 0-2&#xD;
&#xD;
          7. within 35 days after White Blood Cell (WBC) and Neutrophil recovers over 1500 and 500,&#xD;
             respectively&#xD;
&#xD;
          8. sufficient organ function as below within 7 days&#xD;
&#xD;
        (1) Neutrophil : &gt;= 1000 (2) Cr : &gt;= 3.0mg/dl (3) Aspartate aminotransferase (AST), Alanine&#xD;
        transaminase (ALT) : 5 x the upper limit of normal (ULN) for the reference lab (4)&#xD;
        Percutaneous oxygen saturation (SpO2): &gt;= 95% 9) patients who agree contraception until 6&#xD;
        months after the last injection 10) non-candidate for hematopoietic stem cell&#xD;
        transplantation.&#xD;
&#xD;
          1. illegible for hematopoietic stem cell transplantation (HSCT)&#xD;
&#xD;
          2. lack of appropriate donor&#xD;
&#xD;
          3. patients who don't select HSCT at the 1st hematological complete remission (hCR)&#xD;
             timing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. multiple primary cancer&#xD;
&#xD;
          2. autoimmune disease&#xD;
&#xD;
          3. usage of investigational or unapproved drug within 28 days&#xD;
&#xD;
          4. severe organ failure&#xD;
&#xD;
          5. Human Immunodeficiency Virus (HIV) antibody / Hepatitis B surface (HBs) antigen /&#xD;
             Hepatitis C Virus (HCV) antibody positive&#xD;
&#xD;
          6. pregnant woman&#xD;
&#xD;
          7. lactating woman&#xD;
&#xD;
          8. under treatment against active infection&#xD;
&#xD;
          9. difficult to enroll because of mental problem&#xD;
&#xD;
         10. other reasons which investigator judge appropriate for enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jun Nakata, M.D., Ph.D.</last_name>
    <phone>+81668793676</phone>
    <email>mogura@sahs.med.osaka-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Osaka University</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Nakata</last_name>
      <phone>+81668793676</phone>
      <email>mogura@sahs.med.osaka-u.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://sahswww.med.osaka-u.ac.jp/~hmtonc/vaccine/AM05.html</url>
    <description>Related Info</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>February 28, 2021</last_update_submitted>
  <last_update_submitted_qc>February 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Osaka University</investigator_affiliation>
    <investigator_full_name>Yoichi Yamamoto</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

